CN112689506A - 用于治疗移植物抗宿主疾病的组合物 - Google Patents

用于治疗移植物抗宿主疾病的组合物 Download PDF

Info

Publication number
CN112689506A
CN112689506A CN201980050483.7A CN201980050483A CN112689506A CN 112689506 A CN112689506 A CN 112689506A CN 201980050483 A CN201980050483 A CN 201980050483A CN 112689506 A CN112689506 A CN 112689506A
Authority
CN
China
Prior art keywords
ala
leu
gly
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050483.7A
Other languages
English (en)
Chinese (zh)
Inventor
让·德冈兹伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Da Volterra SAS
Original Assignee
Da Volterra SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra SAS filed Critical Da Volterra SAS
Publication of CN112689506A publication Critical patent/CN112689506A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980050483.7A 2018-08-05 2019-08-05 用于治疗移植物抗宿主疾病的组合物 Pending CN112689506A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187409 2018-08-05
EP18187409.0 2018-08-05
PCT/EP2019/071026 WO2020030593A1 (en) 2018-08-05 2019-08-05 Compositions for the treatment of graft versus host disease

Publications (1)

Publication Number Publication Date
CN112689506A true CN112689506A (zh) 2021-04-20

Family

ID=63165229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050483.7A Pending CN112689506A (zh) 2018-08-05 2019-08-05 用于治疗移植物抗宿主疾病的组合物

Country Status (11)

Country Link
US (1) US20210290741A1 (https=)
EP (1) EP3829552A1 (https=)
JP (1) JP2021533150A (https=)
KR (1) KR20210040395A (https=)
CN (1) CN112689506A (https=)
AU (1) AU2019320483A1 (https=)
BR (1) BR112021002105A2 (https=)
CA (1) CA3106433A1 (https=)
IL (1) IL280589A (https=)
MX (1) MX2021001393A (https=)
WO (1) WO2020030593A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218800A1 (en) * 2019-05-06 2022-07-14 Synthetic Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148473A (zh) * 2014-10-08 2017-09-08 合成生物制品有限公司 β‑内酰胺酶制剂及其用途
CN107249609A (zh) * 2014-11-25 2017-10-13 纪念斯隆-凯特琳癌症中心 肠道微生物群和gvhd
CN108135944A (zh) * 2014-11-25 2018-06-08 伊夫罗生物科学公司 益生菌和益生元组合物及其调节微生物组的方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249100B2 (en) 2005-05-18 2012-01-19 Assistance Publique - Hospitaux De Paris Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
MX340822B (es) 2010-02-23 2016-07-26 Da Volterra * Formulaciones para suministro oral de adsorbentes en el intestino.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP2897594B1 (en) 2012-09-21 2020-04-08 Ferring B.V. Pharmaceutical composition
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107148473A (zh) * 2014-10-08 2017-09-08 合成生物制品有限公司 β‑内酰胺酶制剂及其用途
CN107249609A (zh) * 2014-11-25 2017-10-13 纪念斯隆-凯特琳癌症中心 肠道微生物群和gvhd
CN108135944A (zh) * 2014-11-25 2018-06-08 伊夫罗生物科学公司 益生菌和益生元组合物及其调节微生物组的方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEAN DE GUNZBURG ET AL.: "Protection of the Human Gut Microbiome From Antibiotics" *

Also Published As

Publication number Publication date
US20210290741A1 (en) 2021-09-23
JP2021533150A (ja) 2021-12-02
KR20210040395A (ko) 2021-04-13
BR112021002105A2 (pt) 2021-06-01
MX2021001393A (es) 2021-04-12
IL280589A (en) 2021-03-25
CA3106433A1 (en) 2020-02-13
AU2019320483A1 (en) 2021-02-18
EP3829552A1 (en) 2021-06-09
WO2020030593A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
AU772332B2 (en) Probiotic, lactic acid-producing bacteria and uses thereof
US20040127403A1 (en) Methods for treating and preventing Gram-positive bacteremias
AU2009225281A1 (en) Methods and reagents for treating infections of clostridium difficile and diseases associate therewith
US20040147441A1 (en) Methods and reagents for preventing bacteremias
US11129811B2 (en) Methods and compositions to prevent or treat bacterial infections
JP2026035819A (ja) 移植片対宿主病の処置のためのβ－ラクタマーゼ組成物
CN112689506A (zh) 用于治疗移植物抗宿主疾病的组合物
EP3207141A1 (fr) Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
KR20210040997A (ko) 항암제 효능의 개선 방법
HK40096554A (zh) 一种治疗耐碳青霉烯肺炎克雷伯氏菌感染的组合物
JPH10127281A (ja) Ｐｅｇ修飾アルギン酸リアーゼおよびその用途
Rizzello et al. Probiotics in GI Diseases
Tambasco et al. Probiotics in GI Diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210420

WD01 Invention patent application deemed withdrawn after publication